Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Other Events

0

Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Other Events

Item 8.01. Other Events.

On December16, 2016, Novelion Therapeutics Inc. (the
Company) issued a press release announcing that the
1-for-5 share consolidation (the Share Consolidation) of
its common shares (Common Shares), previously announced on
December5, 2016, took effect at 5:00p.m.eastern time on
December16, 2016. At the effective time of the Share
Consolidation, each Common Share issued and outstanding
immediately before the effective time of the Share Consolidation
was automatically converted into one-fifth of one Common Share.
The Share Consolidation affected all shareholders uniformly and
did not affect any shareholders percentage ownership interest in
the Company or proportionate voting power, except for minor
changes and adjustments resulting from the treatment of
fractional shares. No fractional shares were issued in connection
with the Share Consolidation. Any fractional shares that would
otherwise have been issued were rounded down to the nearest whole
share without any reimbursement or payment associated therewith.
Immediately following the effective time of the Share
Consolidation, Novelion is expected to have approximately
18,530,700 Common Shares issued and outstanding. Common Shares
will begin trading on a Share Consolidation-adjusted basis on the
NASDAQ Global Select Market at the opening of trading on
December19, 2016, and on the Toronto Stock Exchange at the
opening of trading on or about December21, 2016. In addition, as
a result of the Share Consolidation, the Company announced an
adjustment to the conversion rate of the 2.00% Convertible Senior
Notes (the Convertible Notes) due 2019 of Aegerion
Pharmaceuticals,Inc., an indirect wholly-owned subsidiary of the
Company, to reflect a conversion rate of 4.9817 Common Shares per
$1,000 principal amount of Convertible Notes.

A copy of the press release announcing the effectiveness of the
Share Consolidation and the adjustment to the conversion rate of
the Convertible Notes is filed as Exhibit99.1 to this Current
Report on Form8-K and is incorporated by reference into this Item
8.01. A specimen common share certificate reflecting the Share
Consolidation is filed as Exhibit4.1 to this Current Report on
Form8-K.

Item 9.01. Financial Statements and
Exhibits.

(d)Exhibits.

ExhibitNo.

Description

4.1

Specimen Common Share Certificate of the Company.

99.1

Press Release, dated December16, 2016.


About Novelion Therapeutics Inc. (NASDAQ:NVLN)

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Novelion Therapeutics Inc. (NASDAQ:NVLN) Recent Trading Information

Novelion Therapeutics Inc. (NASDAQ:NVLN) closed its last trading session up +0.25 at 9.00 with 84,346 shares trading hands.